header logo image


Page 1,058«..1020..1,0571,0581,0591,060..1,0701,080..»

Blissful color-blindness of the young children … – Enid News & Eagle

March 5th, 2017 4:42 pm

Recently the mother of a 5-year-old boy in Louisville, Ky., told her young son he needed a haircut.

He asked if he could get the same haircut as his best friend, because Were going to trick the teacher.

The boy thought if he had the same haircut as his buddy, their pre-K teacher couldnt tell them apart.

Jax, the boy needing the haircut, wanted to get a buzz cut like his friend, Reddy, who is also 5. So he did.

The punchline of this endearing story is that Jax is white, Reddy is black. The difference in their pigment, apparently, never crossed the boys minds when they plotted to fool their teacher.

Would that we all could be that way, seeing each other as friends and fellow human beings rather than as black, white, yellow, red, brown, green, purple or any shade.

Children see only another person whom they like and want to play with, not a person of another race. Prejudice, it seems, comes only with age and experience.

In the classic Rogers and Hammerstein musical South Pacific, there is a song in the second act that highlights this phenomenon.

Young Navy Lt. Cable has fallen in love with a Polynesian girl, Liat, but he knows he cannot marry her because of his familys prejudice.

At the same time, Ensign Nelly Forbush decides she can no longer love French plantation owner Emile because of his two half Polynesian children.

It is a short song with a powerful message, Youve got to be taught to hate and fear.Youve got to be taught from year to year. Its got to be drummed in your dear little ear. Youve got to be carefully taught.Youve got to be taught to be afraid, of people whose eyes are oddly made, and people whose skin is a diffrent shade.Youve got to be carefully taught.Youve got to be taught before its too late, before you are 6 or 7 or 8, to hate all the people your relatives hate, youve got to be carefully taught!

Over the years too many have learned those lessons too well.

In an article published in the St. Louis American, an African-American newspaper in that Missouri city, Roland Bob Harris, a St. Louis native, writes about his time in the Air Force, including his tenure serving at Vance Air Force Base in the late 1950s.

Segregation reigned supreme, Harris wrote. The blacks in Enid literally lived on the other side of the tracks. There were only two black policemen. They could only patrol in the black section of Enid. Enid was a very dismal assignment.

Thank God we have come a long way since the late 1950s, though we still have far to go.

For young airmen assigned to Vance today, this still may be a dismal assignment, but only because of Enids small size and long distance from a major metropolitan area, not because of rampant racism.

We could learn a lot from Jax and Reddy. Color shouldnt matter, period. Of course, neither should your country of origin, how you choose to worship nor who you decide to love.

Why must we be so quick to hate, so eager to distrust, so reluctant to love, so hesitant to accept?

We have, I fear, been carefully taught.

We can only pray thats a lesson Jax and Reddy never learn.

Mullin is senior writer of the News & Eagle. Email him at jmullin@enidnews.com or call 548-8145.

More here:
Blissful color-blindness of the young children ... - Enid News & Eagle

Read More...

Why Puma Biotechnology Inc. Got Hammered Today – Motley Fool

March 5th, 2017 4:41 pm

What happened

Puma Biotechnology (NASDAQ:PBYI) ended the day down 13.8% after Roche (NASDAQOTH:RHHBY) reported that its rival breast cancer drug, Perjeta, had passed its phase 3 trial, dubbed "Aphinity."

Image source: Getty Images.

In Roche's trial, patients either took Perjeta and Herceptin with chemotherapy or just Herceptin with chemotherapy, and then took Perjeta and Herceptin, or just Herceptin, for an additional year. Roche didn't release the full data from the clinical trial, but it did say the triple combination reduced the risk of recurrence of invasive disease or death compared to Herceptin and chemotherapy alone.

The potential to establish a new standard of care where patients take Herceptin and Perjeta for a year could be problematic for Puma Biotechnology because its drug candidate, neratinib, was tested after just Herceptin use, the current standard of care.

Without any data, doctors will likely wonder whether neratinib helps patients that have received Herceptin and Perjeta. And the relapse rate for patients on the current standard of care is already quite low; if adding Perjeta decreases it further, doctors and their patients may decide taking another drug after that isn't worth it, especially given neratinib's side-effect profile.

Investors will have to wait for the full data from Aphinity -- perhaps at the American Society of Clinical Oncology meeting in June -- to know how much better Herceptin plus Perjeta is than Herceptin alone, and how that might affect neratinib's sales, assuming it's approved later this year.

Brian Orelliand The Motley Fool have no positions in any of the stocks mentioned. The Motley Fool has adisclosure policy.

Link:
Why Puma Biotechnology Inc. Got Hammered Today - Motley Fool

Read More...

Richard L. Wang Named Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd., a Joint Venture to Lead … – Business Wire (press release)

March 5th, 2017 4:41 pm

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc., (Nasdaq:KITE) today announced that Richard L. Wang, Ph.D. will be appointed Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd, the companys 50/50 owned joint venture in China with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH,02196.HK).The companies announced the formation of the joint venture in early 2017 to develop, manufacture and commercialize autologous T-cell therapies to treat cancer in China, including Kites lead cell therapy product candidate, axicabtagene ciloleucel. Final registration of the joint venture is ongoing.

We are on the cusp of significant change with CAR-T therapy as a treatment for serious blood cancers, said Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer of Kite. This type of revolutionary change requires deft management, a deep understanding of country-specific requirements, and the ability to unite the strengths of partners, collaborators and the local medical community. Together with Fosun Pharma, we believe Dr. Wang has the unique experience essential for the success of Fosun Kite Biotechnology, CAR-T therapy and axicabtagene ciloleucel in China.

Dr. Wang has extensive experience in the biopharmaceutical industry including US and China based leadership roles at Procter & Gamble, Bristol-Myers Squibb, AstraZeneca and GlaxoSmithKline. He most recently served as Chief Operating Officer of Cellular Biomedicine Group, a U.S. listed clinical-stage immuno-oncology and cell therapy company with operations in China. Previously, Dr. Wang was Senior Site Leader and Head of Operations for GlaxoSmithKline research and development in Shanghai. He obtained a B.S. degree in Cell Biology from the University of Science & Technology of China, a Ph.D. degree in Molecular Biology from the University of Maryland, Baltimore, and a M.B.A. degree from Xavier University in Cincinnati.

Under Dr. Wangs leadership, the joint venture will establish business operations in Shanghai and build a senior leadership team to oversee technical operations and clinical development activities.

AboutKite

Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term durable response and eliminating the burden of chronic care. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors. Kite is based inSanta Monica, CA.For more information onKite, please visit http://www.kitepharma.com. Sign up to follow @KitePharma on Twitter at http://www.twitter.com/kitepharma.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to complete the joint venture registration, the ability of CAR-T therapy to invoke significant change in the treatment for serious blood cancers, and the success of Fosun Kite Biotechnology, CAR-T therapy and axicabtagene ciloleucel in China. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission, including without limitation in its Form 10-K for the year ended December 31, 2016. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Kite assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Visit link:
Richard L. Wang Named Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd., a Joint Venture to Lead ... - Business Wire (press release)

Read More...

Thursday’s Biotech Insights: Aurinia Pharmaceuticals Inc (AUPH), Puma Biotechnology Inc (PBYI) – Smarter Analyst

March 5th, 2017 4:41 pm

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares skyrocketed over 65% this morning, after the drug maker announced top-line results from its AURA-LV Phase IIb study with voclosporin (VCS) in patients with lupus nephritis (LN) that showed at 48 weeks, the study met its complete remission (CR) and partial remission (PR) endpoints.

FBR analyst Vernon T. Bernardino commented, We are impressed with the results, as CRs and PRs at 48 weeks exceeded CRs and PRs at 24 weeks, with one exception. As a reminder, each study arm included standard of care mycophenolate mofetil (MMF) as background therapy and a forced steroid taper. There were no unexpected safety signals or deaths observed in VCS-treated patients. Thus, in addition to strong efficacy, VCS appears to allow safe steroid sparing. We think the results are robust and bode well for a successful Phase III trial, which could make VCS the first approved therapy for LN.

As of this writing,the 4 analysts polled by TipRanks (in the past 6months) rate Aurinia stock a Buy. With a return potential of 39%, the stocks consensus target price stands at $8.50.

Puma Biotechnology Inc (NASDAQ:PBYI) shares lost one-quarter of their value today, after competitor Roche announced positive top-line results from the highly anticipated APHINITY trial,which explores usefulness of Perjeta in adjuvant breast cancer. Recall, Puma has US/EU regulatory applications under review for neratinib in the extended adjuvant setting based on positive Phase 3 ExteNET data.

J.P Morgan Cory Kasimov commented, Todays PR is expectedly light on details, so well have to wait for ASCO to get the full picture. In our view, the future of neratinib in this indication largely rests on the nuances of the data, namely: 1) the magnitude of benefit, 2) the subgroups that drive this benefit (HR+ and/or HR-), and 3) details of the safety profile. The ultimate impact on Puma remains to be seen, but this outcome has obviously taken the near-term best-case scenario off the table. Our prevailing expectation was that on positive APHINITY results, PBYI shares could initially lose roughly 1/3 of their value. That said, investor feedback weve been getting has suggested that this potential dip could provide an opportunity ahead of the ASCO details as well as a number of pending neratinib data points in 1H17.

Out of the 8 analysts polled by TipRanks (in the past 12 months), 6 rate Puma Biotechnology stock a Buy, while 2 rate the stock a Hold. With a return potential of 180%, the stocks consensus target price stands at $79.

Go here to see the original:
Thursday's Biotech Insights: Aurinia Pharmaceuticals Inc (AUPH), Puma Biotechnology Inc (PBYI) - Smarter Analyst

Read More...

CBDual Biotechnology Corp. Announces the Completion of their … – Yahoo Finance

March 5th, 2017 4:41 pm

LOS ANGELES, CA / ACCESSWIRE / March 2, 2017 / CBDual Biotechnology Corp. ("CBDUAL") announced today the completion of the company's new clinical trial center in Southern California.

CBDual's new facility provides patients with easy access to participate in clinical trials of new medical cannabis medications, therapies, and products. CBDual will develop protocols to improve patient safety and data integrity in clinical research trials in compliance with the HIPAA.

The first scheduled trial will study the medicinal and therapeutic effects of CBD on oral health. The study anticipates between 1,000-2,000 patients and will test the effects of different CBD based mouthwashes and toothpastes.

CBDual has recently entered into a cross licensing agreement with Cavitation Technologies, Inc (OTCQB: CVAT; Berlin: WTC). This agreement covers intellectual property involving the application of technology and patented processes to produce high quality pharmaceutical grade cannabis materials with increased bio-availability and increased shelf life.

Dr. Greg Rubin, CEO of CBDual Biotechnology Corp., previously commented, "The improvement of consumer and medical products require the development of the best quality and utilization of the most innovative technologies in order to achieve ultimate results. The impact of the new clinical research brings us one step closer to introducing our new products to the US markets."

Recent breakthroughs in Cannabinoid (CBD) therapies and orally administered products prompt strong forecast for 2017. The Hemp Business Journal estimated that the CBD market will emerge as a $2.1 billion market in consumer sales by 2020. That represents a 700% increase from 2016. According to the National Institute on Drug Abuse, a number of studies have shown that CBD is a non-psychoactive cannabinoid and has a wide range of medical benefits, such as anti- inflammatory and anti-oxidant and many other health related benefits.

About CBDual Biotechnology Corp

CBDual Biotechnology is a privately held; US based Biotechnology Company with a proprietary technology for enhanced oral delivery of bioactive cannabinoids. This technology promotes good gums health and overall dental health due to higher effectiveness of the delivery methodology. Company was founded in 2016 and is headquartered in California with its R&D capability in Israel and Ukraine..

Website: http://www.cbdual.com/

About Cavitation Technologies, Inc.

Founded in 2007, the company designs and manufactures state-of-the-art, flow-through, devices and systems as well as develops processing technologies for use in edible oil refining, renewable fuel production, expeditious petroleum upgrading, algae oil extraction, alcoholic beverage enhancement, water treatment and cannabidiol processing. As an add-on to its existing neutralization systems, the company's patented Nano Reactor allows refiners to significantly reduce both processing costs and environmental impact, while also increasing yield.

Website: http://www.ctinanotech.com/ Follow us on Twitter: https://twitter.com/ctinanotech Like us on Facebook: https://www.facebook.com/ctinanotech

Forward Looking Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding the anticipated installation and the timing of the installation, our intent to continue to focus on research and development, marketing and sales of our unique technology, our belief that our company is positioned for accelerated growth and the expected efforts to be made to enhance our shareholder's value. These forward-looking statements are based largely on the Company's expectations and are subject to a number of risks and uncertainties, certain of which are beyond the Company's control. Actual results could differ materially from these forward looking statements as a result of a variety of factors including, among others, the state of the economy, the competitive environment and our ability to perform the installation as anticipated and other factors described in our most recent Form 10-K and our other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. In light of these risks and uncertainties there can be no assurances that the forward looking statements contained in this press release will in fact transpire or prove to be accurate. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Read More

Cavitation Technologies, Inc.

Contact:

Investor Relations Jessica Steidinger Jessica@ctinanotech.com Phone (818) 718-0905

SOURCE: CBDual Biotechnology Corp.

See more here:
CBDual Biotechnology Corp. Announces the Completion of their ... - Yahoo Finance

Read More...

Jonathan Allen unconcerned about shoulder arthritis – NFL.com

March 5th, 2017 4:41 pm

INDIANAPOLIS -- If the arthritis in Jonathan Allen's surgically repaired shoulders becomes a problem for him during his NFL career, it will have already been an awfully long one.

The former Alabama star said Saturday that doctors have told him the condition shouldn't affect him for 15-20 years, according to the doctors he spoke with.

"The shoulder feels good. Every doctor said if there's a problem, it's after football, way after football. I have no concerns with it at all," Allen said at the NFL Scouting Combine. "... They said I have some arthritis in my left shoulder. It's not really a problem now, but it might be a problem 15, 20 years down the road so I'm not worried about that right now. I'm worried about playing good for whichever team I go to."

NFL Media Insider Ian Rapoport reported Thursday that Allen has mild arthritis in both shoulders.

It certainly never showed up on the field at the college level. Allen was a durable anchor on Alabama's vaunted defensive line for more than two years as a starter. He piled up 22.5 sacks over his last two years in college, playing in all 30 Crimson Tide games over that stretch. With the versatility to play multiple positions along the defensive front, and an ability to defend the run to go with his pass rush skills, Allen is considered one of the elite prospects in the draft.

He repped 225 pounds 21 times on the bench press for NFL scouts Saturday, and said he's feeling fine physically.

"I have no restrictions on anything I do. Like I said I feel good. It's probably the best I've felt in the last four years. I feel good, refreshed, re-charged, ready to go," Allen said.

NFL Network draft expert Mike Mayock ranked Allen as the No. 1 interior defensive lineman in the draft entering the combine.

Follow Chase Goodbread on Twitter @ChaseGoodbread.

Go here to see the original:
Jonathan Allen unconcerned about shoulder arthritis - NFL.com

Read More...

Fashion for People with Arthritis and Other Painful Conditions – Healthline

March 5th, 2017 4:41 pm

Fashion designer Michael Kuluva hasnt let rheumatoid arthritis (RA) get in his way.

But hes acknowledged a notable void in the fashion and beauty industries when it comes to adaptive options and more inclusive designs for people living with an illness or disability.

He isnt alone.

There are online initiatives in the form of hashtags, blogs, Twitter chats, and Instagram accounts that explore the relationship between fashion and chronic illness. It can be a pain for people in pain to dress themselves.

It can also be difficult to find fashionable, stylish options that are also adaptive and functional for anyone with a disability or aching body.

Read more: Get the facts on rheumatoid arthritis

Kuluva is the founder of the label Tumbler and Tipsy, which he debuted at New York Fashion Week.

However, the former figure skater didnt always dream of a career in fashion.

After he retired from his sport in his mid-20s, Kuluva realized that he had another interest and a talent that couldnt be ignored.

He began working as an assistant for a designer despite having no formal training. He eventually secured a scholarship to the Fashion Institute of Design and Merchandising (FIDM).

During his time at FIDM, he found that he was performing well academically but couldnt perform some basic tasks.

I noticed I could not even draw a straight line, and I had other little setbacks. I had trouble cutting fabric and I began comparing myself to other students, Kuluva told Healthline. My joints just weren't doing what they should be. I had pain. Then, one day, walking from class to my car, my back suddenly gave out.

Kuluva first thought he had a kidney stone. He saw a urologist who told him the issue wasnt urological and suggested that Kuluva see a rheumatologist.

After visiting three doctors and waiting months to be seen at the Mayo Clinic, Kuluva was eventually diagnosed with RA. Through trial and error, he found a combination of medications that worked pretty well for controlling his condition.

No medication is ever 100 percent, but my regimen is going well, he said. If I miss a few weeks of treatment, because of travel or fashion shows for example, then I can definitely feel that. I didnt really have issues while figure skating. I had some bursitis, but I dont think it had anything to do with my RA. So, my decision to retire from skating was not related to my rheumatoid arthritis, but Im glad I retired when I did.

Read more: The making of an American Ninja Warrior

After showing a collection that would eventually help to launch the career of model Kendall Jenner, Kuluva started to think about how he could use his art and his platform for good.

Theres been a lot of proud moments a lot of great moments that are unforgettable. Kendall Jenner helped to launch my career and vice versa, he said. This gave me kind of a voice in society. So my CreakyJoints collection was a pivotal moment where I got to express myself within my fashion.

The collection is a collaboration with the arthritis-related nonprofit CreakyJoints, to promote RA awareness on the runway.

CreakyJoints has worked with celebrities like actress Megan Park to promote RA awareness, but this fashion collection came about rather organically.

Real Housewife of New York Jill Zarins daughter was backstage in my dressing room, and we got to talking because she has a form of arthritis, too. It got me thinking, and after our conversation I figured I might contact CreakyJoints after that collection was done, Kuluva recalled.

He said he just wanted to lend his voice to a cause and be an advocate for something.

I like the nonprofit mindset of CreakyJoints, all for the patients. The president, Seth, has [spondyloarthritis], and so he really gets it, Kuluva said. So we all had lunch and brainstormed what we could do together. They pretty much left it up to me. I came up with putting starbursts on all the joints in my SS2017 show. The starbursts, while fashionable, represent the joint pain.

Kuluva said the fashion industry still has a void to fill with adaptive and inclusive fashions for people who are sick or have disabilities. This is especially in terms of shoes and footwear.

Kuluva did acknowledge that some current trends of more comfortable and functional styles may be ideal for people with chronic pain.

As for his own work, he continues to dream big and strives to do more. Kuluva has a history of incorporating charity and social change in his work as a fashion designer.

I was hoping to inspire change with the collection that I did. I hope that it opens eyes and spreads awareness, Kuluva said.

In an interview for The Mighty, Kuluva explained his CreakyJoints collection by saying, It really shows the joints affected by arthritis. Its an explosion of colors on joints that would light up on tests for arthritis.

Being diagnosed with RA at age 28 could have destroyed his career or his vision for the future. But it didnt.

Kuluva advises other young people diagnosed with illnesses like RA to keep looking forward and not hiding their condition.

As long as you're open and honest with your doctor and your family with what is going on with you and your health, you can get the help you need. An organization like CreakyJoints can help you understand that you may have restrictions, but you can still achieve great things, he said.

Read more: Dolls with disabilities gaining in popularity

Kuluva is doing his part to spread awareness and other designers are, too.

Tommy Hilfiger has designed some adaptive clothing for children with special needs and physical disabilities.

Fashion bloggers have fought back against ableism in fashion shoots. (Like Kylie Jenner and Lady Gaga using gilded wheelchairs as props.)

Madeline Stewart has made headlines as a model with Down syndrome.

New York Fashion Week began to use models with disabilities, including amputee Shaholly Ayers.

Beyonc cast disability activist Jillian Mercado as a model in one of her advertising campaigns.

And many more brands are coming out with adaptive clothing that is fashionable and chic, yet still provides necessary comfort and functionality.

Still, many fashions dont have stylish, easy-to-wear or adaptive alternatives, or inclusive runway shows or advertising campaigns.

The beauty industry also lacks variety when it comes to ergonomic and adaptive options for hairstyling tools and makeup brushes.

But designers like Kuluva think that these baby steps toward progress are working in favor of people with health problems or physical disabilities.

I think the industry will get there, he said.

For now, the Arthritis Foundation has a list of approved arthritis-friendly products with the Ease of Use seal of approval, to help people with arthritis dress themselves more easily. They also have suggested footwear brands and options.

Other websites, like the now-defunct Arthriving site from Aleve, have attempted to catalog the best products to help people with arthritis pain function better when it comes to daily activities like drying their hair, cooking, buttoning a blouse, fastening a bra, or tying their shoes.

While that site is gone, there are many blogs that offer tips for living well with chronic pain or limitations in terms of physical mobility and ability.

Read more:
Fashion for People with Arthritis and Other Painful Conditions - Healthline

Read More...

Huddersfield woman’s new self-help group for arthritis sufferers – Huddersfield Examiner

March 5th, 2017 4:41 pm

Trish Sahin was only in her thirties when she first began to suffer sharp pains in her knees.

At the time she was a hockey player and otherwise fit and well. A year later she was diagnosed with osteoarthritis and her life changed forever.

Today, Trish, 58, a former art and design teacher, is severely disabled. She walks with the aid of sticks and lives in permanent pain. Two years ago she had to give up work as a supply teacher in secondary schools because her mobility was so restricted. According to the Health and Safety Executive up to one third of people with a musculo-skeletal problem such as arthritis retire early, give up work or reduce their hours.

She is far from being alone in her suffering and yet the condition itself can be isolating. Osteoarthritis is the most common form of arthritic disease and affects 8m people in the UK. The nature of the disease means that sufferers can end up feeling depressed and reluctant to make the effort to go out and about.

As Trish, who lives in Clayton West, explains: I know a lot of people like me who suffer like this and end up staying in all day. I get frustrated and very, very down at times. You isolate yourself, so you get lonely. I do have friends who I go out with but I have to remember not to talk about my arthritis because people get sick of hearing about it - even though its on your mind all the time.

In order to tackle the problem Trish has signed up to become a Champion Volunteer for the charity Arthritis Care, which runs a project entitled Living Well With Arthritis.

She is hoping to establish a peer support drop-in group in Kirkburton, at which arthritis patients can get together on a regular basis to share experiences and information. She said: It will get me out of the house and, hopefully, get other people out of the house. Its given me a purpose. The group is for people of all ages. I know of one young girl with arthritis who had two knee replacements by the age of 24.

Arthritis is an umbrella term for a vast array of conditions - from gout and lupus to rheumatoid arthritis, which is an auto-immune disease. Trish also has the auto-immune condition giant cell arteritis, an inflammation of blood vessels in the head. Many arthritic diseases are painful enough to require constant pain medication and the use of anti-inflammatory drugs and steroids.

Trish has had two knee replacements and hip surgery and is on a cocktail of medication, including steroids. A side effect has been weight gain, in itself bad news for arthritis sufferers as excess weight puts strain on joints. She recently joined a slimming club to lose the four stones gained in the last two years since taking steroids, but says shes battling against reduced mobility and an appetite stimulated by the drug.

Arthritis Care would like to hear from other arthritis patients in the area willing to work as volunteers at information and drop-in points (theres one at Dewsbury Hospital), run peer support workshops (like Trish) or offer telephone advice sessions on practical subjects such as diet and exercise, pain management and living aids.

For her own group Trish would like to hear from people able to provide transport so that those without their own vehicles can attend.

I want people to share their experiences, says Trish, so we can compare notes on medication, diet, benefits and pain management, that sort of thing.

Over the last couple of years shes faced practical issues, such as finding a single-storey house (a bungalow provided by Kirklees), getting a blue badge for her car, and accessing disability benefits to top up her pension. She understands the frustrations faced by disabled people undergoing fitness for work assessments. Theres an assumption that you are putting it on, she says, and you can have a good day when youre walking better. But the pain is awful. I lie in bed at night and its a dull, throbbing ache, that stops you sleeping. No-one wants to be like this. I get these really black moods, Im on anti-depressants as well as everything else.

Trish believes there may be a genetic component to her arthritis as other members of her family have developed joint problems. Many types of arthritis have no known cause but osteoarthritis may result from injury, obesity and ageing. While the condition cant be cured, Arthritis Care says that early diagnosis, treatment and good management can delay the progression and ease symptoms. However, a survey conducted by the charity last year found that many people wait two years or more before seeking help with painful joints.

If youd like to become a volunteer for Arthritis Care in the Kirklees area or help Trishs venture contact Emma Marshall, Volunteer Co-ordinator, on 07968624377 or EmmaM@arthritiscare.org.uk

Osteoarthritis can cause joint pain and stiffness; it is more common in women and the elderly. It develops when the cartilage protecting bones changes and erodes.

Rheumatoid arthritis affects 700,000 people in the UK and is an auto-immune condition that causes inflammation of the joints.

There are forms of arthritis that affect children and young people, it is not just a condition of the elderly.

By the year 2030 it is estimated that there will be a 50% increase in the number of people living with arthritic conditions in the UK.

Figures from Arthritis Care show that last year around 1 in 5 of the general population consulted their GP about a musculo-skeletal problem such as arthritis and 7.5m working days were lost because of arthritic conditions.

According to the World Health Organisation arthritis is the leading cause of disability.

Losing excess weight, taking exercise and eating a healthy diet - some sufferers, like Trish, recommend a Mediterranean diet - can all help ease the painful symptoms.

Read more:
Huddersfield woman's new self-help group for arthritis sufferers - Huddersfield Examiner

Read More...

Opinion/Commentary: Global stem cell therapy market to showcase growth – The Daily Progress

March 5th, 2017 4:40 pm

LONDON Technavio analysts forecast the global stem cell therapy market to grow at a compound annual growth rate of close to 37 percent during the forecast period, according to their latest report.

The research study covers the present scenario and growth prospects of the global stem cell therapy market for 2017-2021. To determine the market size, the study considers revenue generated from allogenic and autogenic stem cell therapies.

The Americas are the largest regional segment of the global stem cell therapy market, responsible for generating over 56 percent of the total revenue (2016 figures). The region is expected to continue market dominance through the forecast period, driven by increasing demand for stem cell therapy products and investments into R&D.

Technavio analysts highlight the following factors as contributing to the growth of the global stem cell therapy market:

Increase in federal funding in stem cell therapy.

Sapna Jha, one of the lead research analysts at Technavio for medical imaging research, says, Many stem cell research institutes and small companies are involved in cutting-edge R&D and are yielding encouraging results. These institutions are witnessing an increased flow of investments from federal organizations, due to the realization of the importance of regenerative medicine.

The U.S. National Institutes of Health, a major funding government organization invested approximately USD 1.5 billion in stem cell research projects in 2016. Similarly, several state-level organizations such as California Institute for Regenerative Medicine has contributed USD 3 billion to stem cell research in 2014. Such funding will help various research institutes to discover and develop regenerative medicines, which will boost the global regenerative medicine market enormously.

Growing demand for personalized medicine.

The health care sector is creating a high demand for personalized medicine, which could offer game-changing opportunities for the vendors. These medicines offer treatments based on the individual characteristics, needs, and preferences, which will vastly improve the quality of health care. Individuals are increasingly banking their stem cells for future treatments. Research organizations are also extensively exploring ways to develop personalized treatments with stem cells, which could eventually erase the conventional medicine system and help in the effective treatment of various diseases such as diabetes and cancer.

Demand for development of effective drugs for cardiology and degenerative disorders.

There has been an increased demand to develop effective drugs for cardiology and degenerative disorders, for which there were no effective treatment plans before the advent of stem therapies. The discovery of possible cardiac stem cells uncovered new arenas to repair hearts injured due to acute myocardial infarction or coronary artery disease, says Sapna.

Researchers are studying and developing approximately 19 product candidates for the treatment of cardiac disorders, with eight of them in Phase III, and six in Phase II.

Technavio is a global technology research and advisory company. This report was made available through The Associated Press.

Continued here:
Opinion/Commentary: Global stem cell therapy market to showcase growth - The Daily Progress

Read More...

Scientists moving ahead with research to resurrect the dead with stem cells – Blastr

March 4th, 2017 6:44 am

A U.S. biotech company is preparing to start experiments using stem cells to try to stimulate 20 brain-dead patients back to life. And no, this isn't an elevator pitch for a sci-fi horror film.

The Mind Unleashed reports the company Bioquark will be trying to use stem cells to regrow and stimulate neurons to bring the patients back from brain death. It works like this: They implant stem cells in the patient's brain while also infusing the spinal cord with chemicals typically used to try and wake up coma patients. Then, hopefully, brain activity is essentially 'jump-started.' The technique is untested, so these experiments will go a long way toward proving (or disproving) the viability of the process.

Bioquark CEO Ira Pastor said they hope to see some results within 2-3 months after treatment begins, with the long-term goal being to develop techniques for brain-dead patients to eventually be able to make a full recovery. Which is certainly a heady, and ethically tricky, goal. You know, and also kind of scary. Ambitious and potentially live-saving, but still a little freaky.

What do you think of the technique? Is this going to revolutionize brain recovery or be the first step toward the T-virus?

(via The Mind Unleashed)

Original post:
Scientists moving ahead with research to resurrect the dead with stem cells - Blastr

Read More...

A New Breakthrough in Lab-Grown Cells Could Restore Hearing – Futurism

March 4th, 2017 6:44 am

Auditory Illnesses

One of the most common causes of hearing loss is damage to the thousands of hair cells found within the inner ear. These hair cells detect and translate sound waves into nerve signals, enabling us to hear sound. As crucial as these hair cells are to hearing, these are susceptible to damage caused by excessive noise, old age, or certain medications. Once these hair cells are destroyed in a human ear, they dont regenerate.

According to the Centers for Disease Control and Prevention (CDC), sensory hair cell injuryaccounts for 90 percent of hearing loss cases in the United States. Meanwhile, the World Health Organization (WHO) reportsthat about 360 million people worldwide have disabling hearing loss, and 32 million of these are children.

But what if these hair cells could be regrown? Thats the idea behind astudy conducted by a team of scientists from Harvard University and the Massachusetts Institute of Technology (MIT). Their research has long been in the making and is now published in the journal Cell Reports.

In 2012, lead scientist Albert Edge discovered stem cells in the ear called Lgr5+ cells. These were also found in the lining of human intestines, where they actively regenerate every eight days. Edges team found a way to convincethese stem cells to developinto hair cells instead of intestinal cells. The process took a great deal of time, however, and it only yielded 200 hair cells.Now, the team had managed to grow 11,500 hair cells from the Lgr5+ cells in mice, which are among the few mammals whose cells can regenerate when they are newly born.

The researchers achieved this higher yield by adding a new step to their process. After taking the Lgr5+ cells from the mice, they coaxed them to divide within a special growth medium. This increased the number of Lgr5+ cells two-thousandfold. The stem cells were then moved to a different kind of growth culture, at which point certain chemicals were added that turned the Lgr5+ cells into hair cells.

Each human ear has about 16,000 hair cells in itscochlea, the actual hearing organ found deep in the ear canal. These hair cells are divided into outer hair cells and inner hair cells, each with a specialized role in handling sound.

While these lab-grown hair cells seem to have many characteristics similar to these outer and inner hair cells, Edge admits that they may not yet be fully functional. His team tested their technique on a sample of healthy ear tissue taken from a 40-year-old brain tumor patient that underwent a labyrinthectomy. The isolated adult human stem cells did differentiate into hair cells, but not as robustly as the mouse cells had.

Still, neuroscience professor and hair-cell regeneration expert Jeff Corwin from the University of Virginia School of Medicinetold Live Science he found the research to be a very impressive studyby a dream team of scientists. Corwin, who wasnt involved in the study, called it a big advance in sensory hearing cell regeneration. You can see in their paper that they are perfecting their technique as they go along, he added.

While the team works to continue improving their methods, Edge said that their lab-grown hair cells may have one immediate application large sets of the cells can be made and used to test drugs and identify which compounds can heal damaged hair cells or induce regeneration.

Go here to see the original:
A New Breakthrough in Lab-Grown Cells Could Restore Hearing - Futurism

Read More...

We know Dolly the sheep was cloned 20 years ago, but how old was she at birth? – Washington Post

March 4th, 2017 6:44 am

By Jos Cibelli By Jos Cibelli March 3 at 12:41 PM

In 1997 Dolly the sheep was introduced to the world by biologists Keith Campbell, Ian Wilmut and colleagues. Not just any lamb, Dolly was a clone. Rather than being made from a sperm and an egg, she originated with a mammary gland cell of a no-longerliving six-year-old Fynn Dorset ewe.

With her birth, a scientific and societal revolution was also born.

Some prominent scientists thought it was too good to be true. But more animals were cloned: first the laboratory mouse, then cows, goats, pigs, horses, even dogs, ferrets and camels. By early 2000, the issue was settled: Dolly was real and cloning adults was possible.

The implications of cloning animals in our society were self-evident from the start. Our advancing ability to reprogram adult, already specialized cells and start them over as something new may one day be the key to creating cells and organs that match the immune system of each individual patient in need of replacements.

But what somehow got lost was the fact that a clone was born at Day Zero created from the cell of another animal that was six years old. Researchers have spent the past 20 years trying to untangle the mysteries of how clones age. How old, biologically, are these animals born from other adult animals cells?

Decades of cloning research

Dolly became an international celebrity, but she was not the first vertebrate to be cloned from a cell taken from the body of another animal. In 1962, developmental biologist John Gurdon cloned the first adult animal by taking a cell from the intestine of one frog and injecting it into an egg of another. Gurdons work did not go unnoticed he went on to share the 2012 Nobel Prize in physiology or medicine. But it was Dolly who captured our imagination. Was it because she was a warm-blooded animal, a mammal, much closer to human? If you could do it in a sheep, you could do it in us!

Dolly, along with Gurdons frogs from 35 years earlier and all the other experiments in between, redirected our scientific studies. It was amazing to see a differentiated cell an adult cell specialized to do its particular job transform into an embryonic one that could go on to give rise to all the other cells of a normal body. We researchers wondered whether we could go further: Could we in the lab make an adult cell once again undifferentiated, without needing to make a cloned embryo?

A decade after Dolly was announced, stem cell researcher Shynia Yamanakas team did just that. He went on to be the Nobel co-recipient with Gurdon for showing that mature cells could be reprogrammed to become pluripotent: able to develop into any specialized adult cell.

Now we have the possibility of making individualized replacement cells potentially any kind to replace tissue damaged by injury, genetic disorders and degeneration. Not only cells: We may soon be able to have our own organs grown in a nonhuman host, ready to be transplanted when needed.

If Dolly was responsible for unleashing the events that culminate in new methods of making fully compatible cells and organs, then her legacy would be to improve the health of practically all human beings on this planet. And yet I am convinced that there are even better things to come.

Dollys secrets still unfolding

In the winter of 2013, I found myself driving on the wrong side of the road through the Nottingham countryside. In contrast to the luscious landscape, I was in a state of gloom: I was on my way to see Keith Campbells family after his sudden death a few weeks earlier.

Keith was a smart, fun, loving friend who, along with Ian Wilmut and colleagues at the Roslin Institute, had brought us Dolly 15 years earlier. We had met at a conference in the early 1990s, when we were both budding scientists playing around with cloning, Keith with sheep, I with cows. An extrovert by nature, he quickly dazzled me with his wit, self-deprecating humor and nonstop chat, all delivered in a thick West Midlands accent. Our friendship that began then continued until his death.

When I knocked at the door of his quaint farmhouse, my plan was to stay just a few minutes, pay my respects to his wife and leave. Five hours and several Guinnesses later, I left feeling grateful. Keith could do that to you, but this time it wasnt Keith, it was his latest work speaking for him. Thats because his wife very generously told me about the project Keith had been working on at the time of his death. I couldnt hide my excitement: Could it be possible that after 20 years, the most striking aspect of Dollys legacy was not yet revealed?

See, when Dolly was cloned, she was created using a cell from a six-year-old sheep. And she died at age 6 , a premature death for a breed that lives an average of nine years or more. People assumed that an offspring cloned from an adult was starting at an age disadvantage; rather than truly being a newborn, it seemed as though a clones internal age would be more advanced than the length of its own life would suggest. Thus the notion that clones biological age and their chronological one were out of sync and that cloned animals will die young.

Some of us were convinced that if the cloning procedure was done properly, the biological clock should be reset: A newborn clone would truly start at Day Zero. We worked very hard to prove our point. We were not convinced by a single DNA analysis done in Dolly showing slightly shorter telomeres, the repetitive DNA sequences at the end of chromosomes that count how many times a cell divides. We presented strong scientific evidence showing that cloned cows had all the same molecular signs of aging as a non-clone, predicting a normal life span. Others showed the same in cloned mice. But we couldnt ignore reports from colleagues interpreting biological signs in cloned animals that they attributed to incomplete resetting of the biological clock. So the jury was out.

Aging studies are very hard to do because there are only two data points that really count: date of birth and date of death. If you want to know the life span of an individual, you have to wait until its natural death. Little did I know, that is what Keith had been doing back in 2012.

On that Saturday afternoon I spent in Keiths house in Nottingham, I saw a photo of the animals in Keiths latest study: several cloned Dollies, all much older than Dolly at the time she had died, and they looked terrific. I was in awe.

The data were confidential, so I had to remain silent until late last year when the work was posthumously published. Keiths co-authors humbly said: For those clones that survive beyond the perinatal period ... the emerging consensus, supported by the current data, is that they are healthy and seem to age normally.

These findings became even more relevant when in December researchers at the Scripps Research Institute found that induced pluripotent stem cells reprogrammed using the Yamanaka factors retain the aging epigenetic signature of the donor individual. In other words, using these four genes to attempt to reprogram the cells does not seem to reset the biological clock.

The new Dollies are now telling us that if we take a cell from an animal of any age and we introduce its nucleus into a non-fertilized mature egg, we can have an individual born with its life span fully restored. They confirmed that all signs of biological and chronological age matched between cloned and non-cloned sheep.

There seems to be a natural, built-in mechanism in the eggs that can rejuvenate a cell. We dont know what it is yet, but it is there. Our group as well as others are hard at work, and as soon as someone finds it, the most astonishing legacy of Dolly will be realized.

Cibelli is scientific director of the Larcel-Bionand laboratory in Spain and a professor of animal biotechnology at Michigan State University. This article was originally published on theconversation.com.

Read the rest here:
We know Dolly the sheep was cloned 20 years ago, but how old was she at birth? - Washington Post

Read More...

Philanthropy vs. Blindness: What’s the Latest? – Inside Philanthropy

March 4th, 2017 6:43 am

If ever there were a problem that might seem tailor-made for philanthropy, it's fighting blindness. Losing sight is a horrifying fate for anyone to contemplate, and it's not surprising that blindness has motivated some deep-pocketed donors for at least a century. Over the past few decades, significant gains have been made in this area. In the United States, for example, the Foundation Fighting Blindnessco-founded by venture capitalist George Gund in 1971has raised over $600 million to fund research advances to prevent and cure retinal degenerative diseases that affect more than 10 million Americans. Worldwide, a range of efforts have sought to bring poor countries affordable cataract surgery. Cataracts are the main cause of blindness for half of the 40 million or so people who cannot see. Millions of people can see today because of these efforts.

This fight would seem eminently winnable, given that the World Health Organization estimates that 80 percent of blindness is avoidable, meaning it can be either prevented or reversed. Spurred on by that hopeful fact, the WHO galvanized a plan in 1999 called Vision 2020,a global initiative to prevent avoidable blindness, with a coalition that includes a number of foundations and top nonprofits.That milestone is now just three years away, and much work remains.

As usual, one key obstacle to faster progress has been funding. Never mind that the world's 2,500 billionaires now have assets of around $7.6 trillionthere's just never enough private or public money to fight blindness. Today's wealthy spend a fortune on luxuries even as millions of their fellow human beings cannot see. As a practical matter, reducing blindness has to compete with a bunch of other global health priorities, starting with diseases that actually kill people, like malaria and HIV/AIDS.

In addition, there aren't nearly as many major funders focused on preventing blindness as you might think. Very few of the largest U.S. foundations have made this a priority.

The Gates Foundation has patched in and out of this issue over the past 18 years, spending tens of millions fighting neglected tropical diseases that cause blindness, including large grants in the past to the Carter Center, the Task Force for Global Health, and Johns Hopkins University. But blindness hasn't been a big priority lately, at least compared to the foundation's investments in other areas.

Recently, the MacArthur Foundation announced that two of its eight semi-finalists for a special $100 million grant were organizations fighting blindness: Himalayan Cataract and the Carter Center. The fact these two made it into the top tier out of 2,000 proposals underscores the potential for big new money to make a huge impact (which is the goal of Mac's 100&Change competition).

While MacArthur's entry into the blindness space could be a game-changer, the Conrad N. Hilton Foundation stands out as one of the steadier big funders here. In particular, it's worked tirelessly to eliminate trachoma, a major cause of blindness. Trachoma is a result of repeated chlamydia trachomatis infections in the eyes. The infection, which typically starts in infancy or childhood, causes the eyelid to turn inward, resulting in corneal scarring caused by the eyelashes rubbing on the eyeball. Trachoma is incredibly painful, and if left untreated, leads to irreversible blindness. The debilitating disease is endemic in some of the poorest countries in the world.

Hilton uses the World Health Organizations (WHO) SAFE strategy (surgery, antibiotics, facial cleanliness, and environmental improvement) approach to eliminating blinding trachoma in Mali, Niger, and Tanzania. The foundation has played a crucial role in eliminating the disease in Ghana, which achieved its elimination targets in 2014. While this is a major success, Hilton isnt celebrating just yet. The foundation still has blinding trachoma in its sights and just awarded millions in grants to eliminate the disease.

Related: Researching Blindness Treatments? Conrad N. Hilton Foundation is on Your Side

Hilton made a total of $11.725 million in grants to three organizations that know more than a little bit about trachoma and avoidable blindness.

At just under $6 million, Helen Keller International received the largest award in this round. Established over 100 years ago, Helen Keller International has been on the front lines of the global trachoma battle since the 1950s, and has over 120 programs across Africa and Asia. Using the WHO's SAFE strategy as well, Helen Keller administered more than 80.5 million integrated neglected tropical disease (NTD) treatments in six African countries in 2016.

Coming in a close second behind Helen Keller International, the Carter Center received a $5.1 million grant from Hilton. The Carter Center has been a leader for over 30 years in the war against NTDs such as guinea worm, river blindness and trachoma. Since 1999, Carter has implemented the SAFE strategy in Mali and Niger. The Carter Center has facilitated thousands of surgeries and administered more than 500 million doses of antibiotics through its mass drug administration programs. Carter has also backed the construction of nearly 220,000 latrines in Mali and Niger. Better water, sanitation, and hygiene plays a critical role in preventing the spread of trachoma.

The final grant in this round was awarded to Sightsavers, which received $650,000. Sightsavers is a U.K.-based organization that has been working to eliminate avoidable blindness for six decades in over 30 countries around the world. Over the years, the group has supported more than 575 million treatments for blinding and potentially blinding conditions, and backed over 8 million surgeries to restore sight. Caroline Harper, CEO of Sightsavers, called Hiltons donation vital to meeting the WHO target for eliminating blinding trachoma by 2020.

Helen Keller International and the Carter Center are using the Hilton grants for trachoma prevention and elimination programs in Mali and Niger. Sightsavers is using its donation from Hilton to back its work in Mali. Both countries are within reach of their trachoma elimination targets.

Related: Where Have Hiltons Global Grants Been Going Lately?

The Hilton Foundations $11.725 million in grants certainly provides a nice boost toward eliminating trachoma in Mali and Niger, and the leveraging power of those funds could help both countries reach the elimination finish line. Hiltons latest trachoma grants require a dollar-for-dollar match by 2020 from each organization. Meaning, the foundation is effectively mounting a three-year, $23.45 million trachoma eradication campaign.

Read more:
Philanthropy vs. Blindness: What's the Latest? - Inside Philanthropy

Read More...

Texas student pursues major in hopes of fixing mother’s blindness … – kgw.com

March 4th, 2017 6:43 am

Student hopes to cure mpother

Jonathan Munson and Madeleine Dart, KIII 4:51 PM. PST March 03, 2017

CORPUS CHRISTI (KIII NEWS) - Del Mar College student Jessica Lybarger, a mechanical engineering major, said she is pursuing a degree in biomedical engineering so that someday she can build her mother a pair of robotic eyes.

Lybarger's mother was diagnosed seven years ago with diabetic retinopathy. The condition led to her mother going blind in both eyes, despite more than 100 surgeries.

In a post by Del Mar College, Jessica said, "I just want her to enjoy all the memories with us as a family. My mom has missed out on seeing my brother get married, and soon I will get married too. I hope that with the success of my robotics, I can help change the lives of others who suffer from the same condition as her."

See the post below:

Kiii News Reporter Madeleine Dart spoke with Lynbarger Friday and came back with her story.

( 2017 KIII)

Read this article:
Texas student pursues major in hopes of fixing mother's blindness ... - kgw.com

Read More...

Swansea boy with color blindness hoping for return of special glasses – Fall River Herald News

March 4th, 2017 6:43 am

Deborah Allard Herald News Staff Reporter @debsallard

SWANSEA Kids lose their glasses. It happens.

But, when Connor Latessa lost his glasses a few weeks ago, the color went out of his life.

Connor, 13, is color blind. Most of what he sees appears in shades of brown.

But, Connors special glasses allowed him to see a full rainbow of colors until he lost those glasses at school or on the way home from school.

They made everything more colorful and vibrant, Connor said.

Rachel Latessa, Connors mom, said she surprised him with the $600 glasses hed been wanting for months. It was during a Christmas party with the family all there to see Connor try out his new glasses, while they held up colorful balloons.

Connor cried when he got his first look at all the reds and greens hed been missing, and especially when he saw the Christmas lights outside.

When I got them I was very emotional, Connor said. I really didnt know what I was seeing.

He said greens and browns are mixed up to him. And, he has a hard time distinguishing between blues and purples. Orange appears as green, and light blue as pink.

We found out when I was really little, Connor said.

Latessa said she noticed things she found odd when he was young, like calling his light blue blanket pink, and crying when he was given green lollipops, though they were really orange.

Different colors, he would call something else, and hes really smart, Latessa said.

When Connor was 5, she had him examined and found out for sure he was color blind. I wasnt surprised, Latessa said.

Its an affliction carried by the women in Latessas family and passed only to male children. Im a carrier, she said.

Her father saw only in black and white, and got in trouble when he was in school for coloring everything black the most vibrant color to him in the crayon box.

Connor understands everything about the condition, and even made it his science project at Joseph Case Junior High School, where he is a student.

Its because of the X and Y chromosome, Connor said, going on to explain the scientific intricacies. He said it affects one in 10 men and one in 200 women. Hes right, according to several websites.

Latessa said Connor being color blind is just something theyve learned to live with, though the glasses are a big help, especially outside where they work best.

It doesnt affect us too much, Latessa said. At times, Ill see something very colorful, and it makes me sad. I wish he could see it.

When a friend of the Latessa family learned that Connor had lost his beloved glasses, she started an online fundraising campaign and collected $500 in just a few hours.

Latessa said shes still hoping someone finds the glasses before buying a new pair.

The glasses look just like sunglasses and are EnChroma brand, which blends a marriage of color vision science and optical technology, according to its website.

If anyone locates the special glasses, contact Latessa at rmlatessa@aol.com or drop them at the office of Joseph Case Junior High School.

See the original post here:
Swansea boy with color blindness hoping for return of special glasses - Fall River Herald News

Read More...

Indictment: VA sees through veteran’s claim of blindness after catching him driving to the hospital – Hutchinson News

March 4th, 2017 6:43 am

An Army veteran from Reno County has been indicted on federal charges of collecting $63,000 in benefits by pretending to be blind, U.S. attorney Tom Beall announced Thursday.

Billy J. Alumbaugh, 61, and his ex-wife, Debra K. Alumbaugh, both of Turon, each are charged with one count of conspiracy to defraud the government and one count of theft of government funds, according to a news release from the U.S. attorneys office in Wichita.

An indictment unsealed Thursday accuses Alumnbaugh of fraudulently receiving a supplemental monthly pension by claiming he was legally blind and needed assistance to perform routine activities.

Alumnbaugh claimed he was unable to drive and needed assistance with reading medication labels, buying groceries and going to medical appointments, the news release said. The indictment charges him with making periodic trips to the Veterans Administration hospital in Wichita, where specialists couldnt find medical reasons for his blindness.

From 2009 to 2016, while he was receiving assistance, he maintained a Kansas drivers license that did not require corrective lenses and routinely drove his car. In October 2016, he and his ex-wife arrived at the VA hospital, with his ex-wife driving. She also drove when the appointment was over, but they stopped the car after driving a few blocks and switched seats so he could drive, the news release said.

If convicted, the conspiracy charge carries a sentence of up to five years in federal prison and a fine of up to $250,000. The theft charge carries a maximum sentence of 10 years and $250,000.

The Veterans Administration Office of Inspector General investigated the case. Assistant U.S. Attorney Brent Anderson will prosecute the case.

Originally posted here:
Indictment: VA sees through veteran's claim of blindness after catching him driving to the hospital - Hutchinson News

Read More...

Puma Biotechnology Shares Plunge On Plans To Modify Neratinib European MAA, Competitor Roche’s Perjeta Win – Benzinga

March 4th, 2017 6:43 am

Shares of Puma Biotechnology Inc (NASDAQ: PBYI) plunged more than 25 percent following plans to modify the summary of product characteristics (SmPC) in its European Marketing Authorization Application (MAA) for its breast cancer drug neratinib.

The company now plans to restrict the intended population to patients initiating neratinib treatment within one year after completion of adjuvant trastuzumab therapy.

Earlier, the proposed indication was for the "extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab based therapy."

Puma submitted its neratinib MAA last summer.

During the regulators meeting, the timeline for Neratinib was discussed. Neratinib will likely be sequenced immediately after adjuvant trastuzumab. Furthermore, more benefits were observed in the subgroup of patients who received neratinib within one year from prior trastuzumab completion.

Related Link: Here's What To Expect Following Trump's Drug Pricing 'Robbery' Comments

In addition, data from the pivotal adjuvant trastuzumab trials suggest that patients are at higher risk of recurrence closer to completion of adjuvant trastuzumab, and the risk of recurrence may decrease over time.

Puma also noted that the Committee for Medicinal Products for Human Use (CHMP) is continuing to review Puma's MAA and has not yet made a final decision to recommend approval of the drug for the updated or any other indication and there is no guarantee when, if ever, the MAA will be approved.

Separately, Puma reported a wider loss for its fourth quarter. On a GAAP basis, Puma reported a net loss applicable to common stock of $72.7 million, or $2.04 per share, versus a net loss of $61.7 million, or $1.90 per share, a year ago.

Excluding items, the loss came in at $1.22 a share versus loss of $1.23 a share, last year. However, the loss was better than consensus loss estimate of $1.92 a share.

On December 31, 2016, Puma had cash and cash equivalents of $194.5 million and marketable securities of $35.0 million.

Shares of Puma closed Wednesdays trading at $38.05. In the pre-market hours Thursday, the stock plunged 26.41 percent to $28.

According to the verified Twitter account of TheStreet's senior columnist Adam Feuerstein, "Hedge funds that own $PBYI are screaming at sell side analysts to defend the stock."

TheStreet also published on its website a possible connection between Puma's movements and those of Roche Holding Ltd. (ADR) (OTC: RHHBY). Feuerstein and Martin Baccardax wrote: "The Roche AG (RHHBY) breast cancer drug Perjeta notched an important win in the closely followed 'Aphinity' clinical trial, promising to add billions of dollars in sales to the Swiss drugmaker's top line. Perjeta's success spells big trouble for Puma Biotechnology (PBYI), which could see its competeing, but still approved, breast cancer drug neratinib without any patients to treat."

At last check in Thursday's pre-market session, shares of Puma were down 26.54 percent at $27.95. ADR shares of Roche were up 5.75 percent at $32.30.

Posted-In: Biotech Earnings News Health Care FDA Movers Media Trading Ideas Best of Benzinga

2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read more here:
Puma Biotechnology Shares Plunge On Plans To Modify Neratinib European MAA, Competitor Roche's Perjeta Win - Benzinga

Read More...

iShares NASDAQ Biotechnology Index (ETF)(NASDAQ:IBB … – ETF Daily News (blog)

March 4th, 2017 6:43 am

March 3, 2017 6:13am NASDAQ:IBB

From Taki Tsaklanos: Biotechnology stocks are breaking out. They have been consolidating for nearly 20 months. Investors lost interestand that is exactly what smart investors, in general, want to see in order to buy a market.

That is also how bull markets start: when nobody talks about it and only a minority of investors is buying it.

Now here it becomes interesting. InvestingHavens research team has closely followed biotechnology, and has written extensively about it last year. The red line throughout all articles was that smart investors are not in a hurry to buy biotech, but prefer to see which direction biotech would go. This is what was published on InvestingHaven until fall of last year:

Biotechnology Close To A Major Breakdown Level

Health Sector Testing All-Time Highs In 2016, Biotech A Buy After Breaking Out

Alert: Biotechnology and Health Sector Testing Long Time Support

Biotechnology Stocks Have News For Investors: It is Now or Never

In other words, on several occasions last year biotechnology stocks were ready to break down, but eventually they did not. The market refused to go lower, and that was a very important observation, which was shared with our readers: Biotechnology Stocks Refusing To Break Down

Then, something very interesting happened in January: Biotech And Health Care Stock Market Sector Showing Signs Of Life. That was the first sign that biotechnology stocks could go higher.

Today, they are attempting to break out.

The most interesting part was what InvestingHavens team wrote last year in April: Biotechnology Sentiment At Multi-Year Extremes. What Should Investors Do? Right at a time when a major breakout attempt in biotechnology stocks was at play, at a time when sentiment was extremely bullish, we wrote this:

What does all this mean to investors? Combining chart patterns with sentiment data is very useful for investors. We believe that a short term top has developed. Biotechnology needs to cool off a bit, which means a retracement is the most likely outcome for the coming weeks. The key is to watch how far the retracement will go: if prices remain within the existing pattern, above support, there is an opportunity for investors to buy the dips. As long as prices remain within the current chart pattern, it is not a good idea to short this market, unless you are a very short term oriented trader.

As a reminder, it was when IBB was trading at 280 points, in April last year, right before it fell 15 percent. Astute readers were very happy, and they keep on thanking us for our wise words.

Right now, biotechnology stocks are going through a serious attempt to break out from their 20-month consolidation period. If the 300 level in IBB holds for at least 5 consecutive days, biotech will go higher in the coming weeks and months.

The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) was unchanged in premarket trading Friday. Year-to-date, IBB has gained 12.97%, versus a 6.59% rise in the benchmark S&P 500 index during the same period.

IBB currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #2 of 36 ETFs in the Health & Biotech ETFs category.

This article is brought to you courtesy of Investing Haven.

Tags: biotech Health Care NASDAQ:IBB Taki Tsaklanos

Categories: NASDAQ:IBB

Continued here:
iShares NASDAQ Biotechnology Index (ETF)(NASDAQ:IBB ... - ETF Daily News (blog)

Read More...

Rheumatoid arthritis: New treatment option for difficult-to-treat patients – Science Daily

March 4th, 2017 6:41 am
Rheumatoid arthritis: New treatment option for difficult-to-treat patients
Science Daily
Nowadays, treatments for rheumatoid arthritis are changed very quickly, once it is established that one is failing to effect any significant improvement. This means that many patients can be helped very quickly. On the other hand, there are patients ...

Continue reading here:
Rheumatoid arthritis: New treatment option for difficult-to-treat patients - Science Daily

Read More...

7 Essential Oils for Arthritis – Care2.com

March 4th, 2017 6:41 am

Most people think that aromatherapy is all about bath and beauty products, but it is so much more than that. Ive used aromatherapy in the protocols for many different health conditions with great results for over 25 years. Here are some of my preferred essential oils for rheumatoid arthritis, osteoarthritis, gout (a form of arthritis in the big toe) and fibromyalgia, which is technically a form of arthritis that affects the muscles and soft tissues of the body:

Use diluted in small amounts topically for healing joint pain. Black pepper essential oil provides a pleasant warming effect on the joints while its analgesic compounds go to work reducing pain. Because it is so strong, it can be a bit harsh on sensitive skin, so be sure it is well dilutedno more than one or two drops per teaspoon of carrier oil.

This highly effective natural analgesic oil works on most types of pain, including both rheumatoid arthritis and osteoarthritis, as well as gouta type of arthritis of the big toe. Because it is extremely potent, use only one drop to one hundred drops, or about one teaspoon of carrier oil after first conducting a skin patch test. Avoid using if you have extremely sensitive skin.

Ginger essential oil brings a soothing warmth when applied to arthritic joint, but it is also great for easing the muscular pain and stiffness of fibromyalgia. Use no two to three drops in a teaspoon of carrier oil and apply topically to affected joints.

Both a pain reliever and nervous system relaxant, lavender is good for easing joint and muscle aches, as well as easing stiffness. If pain is keeping you awake at night, lavender essential oil is also great for sleep, particularly if a drop or two of the essential oil is rubbed on the soles of the feet or palms of the hands before bed. While most essential oils need to be diluted, lavender can often be tolerated neat (undiluted) by most people. However, if you have extremely sensitive skin, dilute two drops of lavender in about 4 drops of a carrier oil like fractionated coconut or apricot kernel oil.

Lemongrass oil is useful for toning the connective tissues and can be helpful when the tendons no longer hold the joints with precision. Dilute in few drops in a teaspoon of carrier oil.

Marjoram oil can be used for easing muscle aches and stiffness along with helping to heal bruises and joint sprains. It is a good choice for topical use for those with fibromyalgia, which is a form of arthritis. It helps with pain but also alleviates muscle tightness. Avoid marjoram essential oil if you have epilepsy.

Peppermint contains analgesic compounds that reduce pain and inflammation. Like lavender, it can usually be tolerated on the skin in its neat form (undiluted) to help reduce pain. A little goes a long way as this oil leaves an intense cooling sensation on the skin. Use one drop and massage into painful or inflamed joints. Wash hands immediately and avoid eye contact.

Make sure you select high quality, pure, undiluted essential oils. While you may end up diluting the oils yourself, most of the oils on the market are diluted in less-than-desirable oils. High quality oils cost more than the cheap varieties on the market but are worth the increased price. Many cheap varieties can also contain synthetic versions of the oils, which offer no therapeutic value and may actually be harmful. But, worse than that, many cheap oils are adulterated with solvents used during the extraction process or toxic pesticides used in the growing process of the herbs from which the oils are extracted.

After diluting the oil in carrier oil, always conduct a 48-hour patch test on a small inconspicuous part of your skin to determine whether you have any sensitivity to the essential oils.

Related:Dont Believe in Herbal Medicine? 10 Things to Change Your MindThe 5 Best Herbs to Soothe Your NervesShould You Actually Starve a Fever?

Dr. Michelle Schoffro Cook, PhD, DNM is the publisher of the free e-news Worlds Healthiest News, president of PureFood BC, and an international best-selling and 20-time published book author whose works include: Arthritis-Proof Your Life: Secrets to Pain-Free Living Without Drugs.

Disclaimer: The views expressed above are solely those of the author and may not reflect those of Care2, Inc., its employees or advertisers.

Go here to see the original:
7 Essential Oils for Arthritis - Care2.com

Read More...

Page 1,058«..1020..1,0571,0581,0591,060..1,0701,080..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick